Table 2 Classification of optical coherence tomography (OCT) morphological features at baseline and 6 months in treatment-naïve and previously treated eyes (%).

From: Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Group

Status

Fovea

INL

OPL

DRT

SRF

DRIL

EZ(-)

ERM

VMT

Naïve

0–0

14.9

34.3

25.4

40.3

73.1

67.2

67.2

79.1

92.5

Naïve

0–1

0.0

1.5

1.5

1.5

1.5

1.5

3.0

6.0

1.5

Naïve

1–0

40.3

31.3

38.8

28.4

23.9

7.5

6.0

0.0

3.0

Naïve

1–1

44.8

32.8

34.3

29.9

1.5

23.9

23.9

14.9

3.0

Pre-Treated

0–0

9.5

19.7

21.1

53.1

85.7

59.9

46.9

76.9

98.6

Pre-Treated

0–1

2.0

4.1

2.7

4.1

1.4

8.2

5.4

0.7

0.0

Pre-Treated

1–0

32.7

23.8

23.1

12.2

12.9

8.2

5.4

2.0

1.4

Pre-Treated

1–1

55.8

52.4

53.1

30.6

0.0

23.8

42.2

20.4

0.0

  1. OCT findings were classified into four categories: 0–0, absent at both baseline and 6 months; 0–1, newly appeared at 6 months; 1–0, resolved at 6 months; and 1–1, present at both time points. The table shows the percentage of eyes exhibiting each pattern for the following OCT features: cystoid macular edema (CME) in the fovea, inner nuclear layer (INL), and outer plexiform layer (OPL); diffuse retinal thickening (DRT); subretinal fluid (SRF); disorganization of the retinal inner layers (DRIL); ellipsoid zone disruption (EZ[-]); epiretinal membrane (ERM); and vitreomacular traction (VMT).